CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study Aortic Valve Stenosis Treatment Disparities in the Underserved JACC Council Perspectives 2019 Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD ESC Clinical Practice Guidelines Relationship Between Hospital Surgical Aortic Valve Replacement Volume and Transcatheter Aortic Valve Replacement Outcomes Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Noninvasive Nuclear SPECT Myocardial Blood Flow Quantitation to Guide Management for Coronary Artery Disease Chimney technique in a TAVR-in-TAVR procedure with high risk of left main artery ostium occlusion Impact of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation on Patients With Chronic Kidney Disease: Subgroup Analysis From ULTIMATE Trial Transcatheter versus Surgical Aortic Valve Replacement in Patients with Prior Cardiac Surgery in the Randomized PARTNER 2A Trial
|<<... 95 96 97 98 99 100 101 ...>>|

Consensus2019 Sep 6. pii: S0167-5273(19)32502-1.

JOURNAL：Int J Cardiol. Article Link

A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus

Farmakis D, Agostoni P, Baholli L et al. Keywords: acute heart failure; advanced heart failure; dobutamine; inodilators; inotropes; levosimendan; milrinone; norepinephrine

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top